afimoxifene

Phase 2Small molecule

NNorthwestern University

afimoxifene is one of 25 small molecule programs targeting Breast Carcinoma in Situ. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast Carcinoma in SituActive, not recruiting

Breast CancerActive, not recruiting

Breast Carcinoma in SituPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Gemzar

GGynecologic Oncology Group

Preclinical

22 3

Adenocard

Astellas

Preclinical

1 4

Lexiscan

Astellas

Preclinical

1 5

afimoxifene

NNorthwestern University

Phase 2

2 6

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 7

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 8

Acupan

YYonsei University

Preclinical

1 9

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 10

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer2 trials

Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT03063619·194 enrolled

Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast

Active, not recruiting·NNorthwestern University·Phase 2·NCT04009044·156 enrolled

Breast Carcinoma in Situ1 trial

4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ

Completed·NNorthwestern University·Phase 2·NCT00952731·27 enrolled

Ductal Carcinoma in Situ1 trial

Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

Completed·NNorthwestern University·Phase 2·NCT02993159·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for afimoxifene. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — afimoxifene compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for afimoxifene. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Northwestern University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNorthwestern University

afimoxifene

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer2 trials

Breast Carcinoma in Situ1 trial

Ductal Carcinoma in Situ1 trial

References

Drug Info

Quick Facts

Related News